TP53 and cancer: Although it remains to be determined how inhibition of P-TEFb augments apoptosis by sub-lethal doses of 5-FU, these findings nevertheless suggest that selective targeting of CDK7 and P-TEFb can sensitize cancer cells to p53 activators by stimulating both apoptosis-initiating pathways.